(NVCN) Increases Size And Prices Offering Of Common Shares

NASDAQ: NVCN
TSX: NVC

VANCOUVER, Jan. 29, 2015 – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) is pleased to announce that due to market interest, it has increased the size of its previously announced underwritten public offering from 8,000,000 common shares to 10,500,000 common shares of the Company. The Company also announced that it has priced the offering at US$7.19 per common share (the “Offering Price“) for aggregate gross proceeds of US$63,559,600 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company and the Selling Securityholders.  The Company is offering 8,840,000 of the 10,500,000 common shares in the offering. The remaining 1,660,000 common shares are being offered by certain directors, officers and employees of the Company (the “Selling Securityholders“).

The Company has also granted the underwriters an over-allotment option to purchase up to an additional 1,575,000 common shares from the Company at the Offering Price, exercisable for a period of 30 days following closing of the offering. Leerink Partners LLC is acting as the sole book-running manager for the offering. Canaccord Genuity Inc. and JMP Securities LLC are acting as co-lead managers for the offering. Ladenburg Thalmann & Co. Inc. is acting as co-manager for the offering.

Closing of the offering will be subject to customary closing conditions, including listing of the common shares on the TSX and NASDAQ and any required approvals of the TSX, and is expected to occur on or about February 3, 2015.

The Company anticipates using the net proceeds of the offering (i) to complete the TIARA-I Feasibility Study; (ii) to initiate a U.S. Investigational Device Exemption Study for Tiara; (iii) to further develop and refine Tiara; (iv) to advance the commercialization of Reducer in Europe; (v) to initiate a U.S. Investigational Device Exemption Study for Reducer; and (vi) for general corporate purposes.

The securities described above are being offered pursuant to a shelf registration statement (including a prospectus) previously filed with and declared effective by the Securities Exchange Commission (“SEC“)  on May 14, 2014 and a corresponding Canadian base shelf prospectus dated May 13, 2014, filed with the securities regulatory authorities in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, Canada. All securities being sold in the offering are being sold only in the United States. A final prospectus supplement relating to the offering will be filed with the SEC and with the securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, Canada.

A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be available for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 4814, or by email at Syndicate@leerink.com.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction. None of the underwriters of the offering is registered as a dealer in any Canadian jurisdiction and accordingly, the underwriters will only sell the offered shares in the United States.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Tiara™ technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; the closing of the offering; regulatory approvals of the offering; the merits and the Company’s defence of the lawsuit filed by CardiAQ, our anticipated use of proceeds from any financings, a history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with Canadian securities regulators. No assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.